|
US5989867A
(en)
|
1996-09-23 |
1999-11-23 |
Knappe; Andrea |
DNA encoding IL-10-like homologue; related reagents
|
|
JP4793971B2
(ja)
*
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
|
US8809504B2
(en)
*
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
EA200802289A1
(ru)
|
2006-05-08 |
2009-04-28 |
Филоджен Спа |
Направляемые к мишени антителами цитокины для терапии
|
|
WO2008130382A2
(en)
|
2006-10-31 |
2008-10-30 |
East Carolina University |
Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
|
|
ES2536772T3
(es)
|
2007-09-21 |
2015-05-28 |
The Regents Of The University Of California |
El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
|
|
WO2009056268A1
(en)
|
2007-10-30 |
2009-05-07 |
Philogen S.P.A. |
An antigen associated with rheumatoid arthritis
|
|
NZ592420A
(en)
|
2008-10-02 |
2012-12-21 |
Emergent Product Dev Seattle |
Cd86 antagonist multi-target binding proteins
|
|
US9249225B2
(en)
*
|
2010-05-26 |
2016-02-02 |
Regents Of The University Of Minnesota |
Single chain variable fragment anti-CD133 antibodies and uses thereof
|
|
WO2012045334A1
(en)
|
2010-10-05 |
2012-04-12 |
Synthon Bv |
Biologically active il-10 fusion proteins
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2736535B1
(en)
|
2011-07-27 |
2018-10-17 |
Philogen S.p.A. |
Il-12 immunoconjugate
|
|
KR102277469B1
(ko)
|
2011-12-12 |
2021-07-15 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
|
|
CN104245722A
(zh)
|
2012-02-29 |
2014-12-24 |
Ambrx公司 |
白细胞介素-10多肽结合物和其用途
|
|
CA2876285A1
(en)
*
|
2012-08-08 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-10 fusion proteins and uses thereof
|
|
RU2612878C2
(ru)
*
|
2012-10-03 |
2017-03-13 |
Филоджен С.П.А. |
Антигены, ассоциированные с воспалительным заболеванием кишечника
|
|
KR20160043927A
(ko)
|
2013-03-14 |
2016-04-22 |
파카쉬 길 |
세포 표면 grp78에 결합하는 항체를 사용하는 암 치료
|
|
AU2014257906A1
(en)
|
2013-04-26 |
2015-12-10 |
Philogen S.P.A. |
IL4 conjugated to antibodies against extracellular matrix components
|
|
WO2015117930A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukine 10 immunoconjugates
|
|
CN106659774A
(zh)
|
2014-05-16 |
2017-05-10 |
贝勒研究院 |
用于治疗自身免疫和炎性病症的方法和组合物
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
AU2015364396B2
(en)
|
2014-12-19 |
2018-08-09 |
Alkermes, Inc. |
Single chain Fc fusion proteins
|
|
CA2986755A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
KR101811050B1
(ko)
|
2015-09-02 |
2017-12-21 |
경북대학교 산학협력단 |
항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
|
|
WO2017091611A1
(en)
|
2015-11-23 |
2017-06-01 |
Immungene, Inc |
Enhanced cancer immunotherapy using antibody-interferon fusion molecules
|
|
UY37003A
(es)
|
2015-12-04 |
2017-06-30 |
Novartis Ag |
Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
|
|
CN106349393B
(zh)
*
|
2015-12-21 |
2020-10-30 |
合肥立方制药股份有限公司 |
一种增强抗体药物稳定性的结构
|
|
CA3044556C
(en)
|
2016-04-12 |
2020-11-17 |
Philogen S.P.A. |
Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
WO2018156791A1
(en)
|
2017-02-22 |
2018-08-30 |
Aleta Biotherapeutics Inc. |
Compositions and methods for tumor transduction
|
|
EP3625253A4
(en)
*
|
2017-05-16 |
2021-03-24 |
Scalmibio, Inc. |
ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
|
|
WO2019201866A1
(en)
*
|
2018-04-16 |
2019-10-24 |
Swedish Orphan Biovitrum Ab (Publ) |
Fusion protein
|
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
JP2022524018A
(ja)
|
2019-03-06 |
2022-04-27 |
デカ バイオサイエンシーズ， インコーポレイテッド |
Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
|
|
US20210214782A1
(en)
|
2020-01-09 |
2021-07-15 |
Deka Biosciences, Inc. |
Method of using genetic markers, single nucleotide polymorphisms and/or indels to determine responsiveness to il-10 or il-10 derivative treatment
|
|
AU2021257439A1
(en)
|
2020-04-13 |
2022-12-15 |
University Health Network |
Methods for treating cytokine release syndrome
|
|
CA3186753A1
(en)
*
|
2020-07-20 |
2022-01-27 |
John Mumm |
Dual cytokine fusion proteins comprising il-10
|
|
CA3215528A1
(en)
|
2021-05-11 |
2022-11-17 |
Salvatore Albani |
Chimeric antigen receptors and modified cells comprising the same
|
|
JP2024546938A
(ja)
|
2021-12-13 |
2024-12-26 |
デカ バイオサイエンシーズ， インコーポレイテッド |
マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質
|
|
JP2024546999A
(ja)
|
2021-12-16 |
2024-12-26 |
デカ バイオサイエンシーズ， インコーポレイテッド |
Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー
|
|
CN118900697A
(zh)
|
2022-02-22 |
2024-11-05 |
德卡生物科学公司 |
使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法
|